Last reviewed · How we verify

High Dose Trivalent Inactivated Influenza Vaccine

Sanofi Pasteur, a Sanofi Company · FDA-approved active Biologic Quality 5/100

High Dose Trivalent Inactivated Influenza Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently FDA-approved. Also known as: Fluzone® High Dose.

At a glance

Generic nameHigh Dose Trivalent Inactivated Influenza Vaccine
Also known asFluzone® High Dose
SponsorSanofi Pasteur, a Sanofi Company
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about High Dose Trivalent Inactivated Influenza Vaccine

What is High Dose Trivalent Inactivated Influenza Vaccine?

High Dose Trivalent Inactivated Influenza Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.

Who makes High Dose Trivalent Inactivated Influenza Vaccine?

High Dose Trivalent Inactivated Influenza Vaccine is developed and marketed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is High Dose Trivalent Inactivated Influenza Vaccine also known as anything else?

High Dose Trivalent Inactivated Influenza Vaccine is also known as Fluzone® High Dose.

What development phase is High Dose Trivalent Inactivated Influenza Vaccine in?

High Dose Trivalent Inactivated Influenza Vaccine is FDA-approved (marketed).

Related